Lung Vision System

by Body Vision Medical  · Based in United States →AI-Powered Lung Imaging Technology for Early Cancer Detection
Cardiothoracic Surgery Interventional Radiology Pulmonology

Contact for pricing
Regulatory Status Disclosed

Overview

The LungVision® System by Body Vision Medical is an AI-powered, intraoperative imaging and navigation system designed to revolutionize lung cancer diagnostics and interventions. It transforms images from any conventional 2D C-arm into real-time 3D images, providing pulmonologists and thoracic surgeons with enhanced visualization and guidance during bronchoscopy procedures.

Utilizing proprietary AI Tomo® technology, LungVision corrects for CT-to-body divergence, a common challenge in traditional navigation systems, and offers visual tool-in-lesion confirmation. This enables clinicians to accurately locate and biopsy even small, peripheral lung lesions with greater precision, confidence, and simplicity.

The system is hardware-light, offering an affordable, low-cost solution with a small, mobile footprint, and seamlessly integrates with existing 2D and 3D C-arms, navigation platforms, bronchoscopes (including robotic), and biopsy tools. LungVision has demonstrated improved diagnostic yields, approaching 90-95%, and significantly reduces radiation exposure compared to 3D C-arms.

It supports comprehensive workflow from planning (including virtual bronchoscopy) to real-time navigation and lesion localization, aiming to facilitate earlier diagnosis and more effective treatment of lung cancer.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered 3D imaging from 2D C-arms
  • Real-time intraoperative navigation and lesion localization
  • Correction for CT-to-body divergence
  • Augmented fluoroscopy with tool-in-lesion confirmation
  • Compatibility with existing bronchoscopes, C-arms, and biopsy tools (including robotic)
  • Reduced radiation exposure (up to 1/5 of 3D C-arms)
  • Affordable, hardware-light, mobile footprint
  • Improved diagnostic yield (approaching 90-95%)
  • Virtual bronchoscopy for pathway planning
  • C-Arm Based Tomography (CABT)

Use Cases

  • Peripheral pulmonary nodule biopsy
  • Early lung cancer diagnosis
  • Image-guided navigation during bronchoscopy procedures
  • Delivery of localized therapies
  • Diagnosis and treatment in a single-anesthesia event
  • Accessing smaller, hard-to-visualize, and more peripheral lesions

What Physicians Need to Know

Key Capabilities
AI-powered real-time 3D imaging from any 2D C-arm, augmented fluoroscopy, and virtual bronchoscopy for real-time navigation and guidance during bronchoscopy procedures. It offers real-time tool-in-lesion confirmation, pathway planning, and corrects for CT-to-body divergence, enabling access to small and peripheral lung lesions.
Clinical Utility
Significantly improves diagnostic yield for peripheral pulmonary nodules, with reported yields approaching 90% and beyond, including 81.8% standalone, 91.1% with Ethicon Monarch, and 94.5% with Ion by Intuitive. It facilitates earlier and more accurate lung cancer diagnosis, reduces procedural duration, and enhances physician confidence, allowing for biopsy of smaller lesions and potential for localized therapies.
Integration Options
Designed for seamless integration with existing standard bronchoscopy suite equipment, including 2D and 3D C-arms, various navigation platforms, standard bronchoscopes, robotic bronchoscopy systems (e.g., Ion by Intuitive, Ethicon Monarch), and standard biopsy tools. Its hardware-light design promotes broad compatibility.
Compliance Status
Cleared by the U.S. FDA (LungVision Imaging and Navigation System in May 2017, LungVision Tool in May 2018, LungVision 2.0 System in May 2019). It also holds CE marking (2021) and has received regulatory approvals in India (September 2025) and Singapore (August 2025).
Pricing Model
Positioned as an affordable, low-cost solution with lower capital and per-case costs compared to traditional electromagnetic navigation bronchoscopy systems, robotics, and cone-beam CT. It aims to minimize capital expenditures and offers optional disposables to manage per-procedure costs.
User Experience
Emphasizes ease of use, empowering clinicians with real-time intraoperative imaging for greater precision and simplicity. Recent software updates (v2.27) have further improved the pathway planning experience and overall user interface.
Support Quality
Comprehensive support includes initial clinical training and ongoing case support, refresher training, education for new staff, and advanced training for experienced users. Extended warranty service plans are available, backed by a commitment to high-level customer service.
Implementation Complexity
Features a hardware-light design that integrates with existing standard equipment, offering universal compatibility with most fluoroscopic C-arm models. This approach minimizes the need for significant infrastructure changes, making it a portable, small, and seamless addition to the bronchoscopy suite.
Evidence Base
Supported by multicenter clinical trials, with over 400 procedures conducted in the U.S. by May 2019 and exceeding 2,000 procedures by December 2022. Peer-reviewed publications demonstrate diagnostic accuracy (e.g., 88.2% at 12 months follow-up) and high diagnostic yields.
Physician Tip

Leverage LungVision's real-time 3D imaging and AI Tomou00ae technology to overcome CT-to-body divergence, especially for small or difficult-to-access peripheral lung nodules. Integrate it with your existing C-arm and robotic bronchoscopy platforms to enhance navigation and confirm tool-in-lesion placement, thereby maximizing diagnostic yield and potentially reducing procedure time and radiation exposure. Consider the comprehensive training and support offered to optimize adoption and clinical outcomes.

The LungVision System is designed for broad compatibility, seamlessly integrating with virtually any 2D C-arm, various navigation platforms, and both standard and robotic bronchoscopes (e.g., Ion by Intuitive, Ethicon Monarch). This 'agnostic' approach allows healthcare providers to utilize their existing imaging hardware without significant upgrades, making it a versatile addition to diverse clinical settings. It also integrates with standard biopsy instruments, including cryoprobes.

Details

Category Oncology AI, Radiology & Imaging AI, Surgical AI
Pricing Contact for pricing
  • Not publicly disclosed; described as an affordable, low-cost solution with lower total cost of ownership than alternatives
DeploymentOn-premise hardware with integrated software (main unit and tablet).
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status Yes AI-estimated

The Lung Vision System received 510(k) FDA clearance (K183593) on April 18, 2019, as an image processing and radiological system. It is intended to enable users to segment previously acquired 3D CT datasets and overlay and register these with live X-ray images to support catheter/device navigation during pulmonary procedures.

Integrations
EHR Not specified
Specialties Cardiothoracic Surgery, Interventional Radiology, Pulmonology

What the Web Says

The Lung Vision System by Body Vision Medical is an AI-assisted navigation and augmented fluoroscopy system designed to improve the diagnosis of peripheral pulmonary nodules. It integrates pre-procedural 3D CT scans with real-time intraoperative fluoroscopy, allowing physicians to visualize nodules not typically visible with conventional fluoroscopy. The system has received FDA clearance and aims to enhance diagnostic yield and safety in lung nodule biopsies.

Overall: Positive

Strengths

  • Improved diagnostic yield for peripheral lung lesions (81% vs. 64% in one study).
  • Facilitates localization of nodules not visible with traditional fluoroscopy.
  • Increases sample adequacy for molecular testing.
  • High safety profile with minimal complications.
  • Minimally invasive approach for early detection and characterization of lung nodules.
  • Integrates AI algorithms for precise targeting.

Limitations

  • No specific cons were identified in the provided search results.
  • Limited information available from independent tech reviewers, Reddit, G2, or Capterra.
  • One study reported mild to moderate bleeding complications in 21% of procedures, though no severe bleeding or pneumothorax.
  • One case of atrial fibrillation was reported in a study, managed medically.

Based on reviews from: Thorax, ResearchGate, Innolitics (FDA 510(k) listings), Scribd (Abstracts of Italian Society of Thoracic Endoscopy, Artificial Intelligence and Machine Learning (AIML) - Enabled Medical Devices FDA), Volza (HSN Code used in Israel), Google Scholar (referencing various medical journals)

Last updated: 2026-07-18

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Lung Vision System

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Decisions Advisors
Australia Medical Imaging Market Size, Shares, Trends To 2035
In March 2025, the Therapeutic Goods Administration (TGA) approved Body Vision Medical's AI-powered LungVision intra-operative imaging system for use in Australia. This approval is part of a broader trend of technology advancements in the Australian medical imaging market, including AI-assisted diagnostics.
2025-11
Innolitics (FDA 510(k) Database)
LungVision (K240943) u2014 FDA 510(k)
The LungVision system received FDA 510(k) clearance (K240943) on October 1, 2024, for radiology use. This regulatory announcement indicates the system's approval for assisting clinicians in processing radiological images of the lungs.
2024-10
Journal of Clinical Medicine (MDPI)
Abstract 10 (Oral Presentation): Initial Experience of Ultrathin Cryobiopsy Combined with Lung Vision Platform for Pulmonary Nodules
An abstract from the Italian Society of Thoracic Endoscopy (SIET) 2024 Annual Congress highlights the initial experience of integrating an ultrathin cryoprobe with the Lung Vision system for pulmonary nodules. The study, conducted from January to May 2024, reported a diagnostic yield of 71.4% and a favorable safety profile for early detection and characterization of lung nodules.
2024-10
Beyond Air Press Release
Beyond Airu00ae Appoints David Webster as Chief Commercial Officer
Beyond Air, Inc. announced the appointment of David Webster as Chief Commercial Officer, effective July 8, 2024. Webster previously served as CEO at Body Vision Medical, where he led the global commercialization of the Lung Vision system.
2024-06
Lancashire and South Cumbria Integrated Care Partnership
Lung Vision System - Accelerating Lung Cancer Diagnosis and Care
The Lung Vision System was a finalist for the 2023 HSJ Award in Modernising Diagnostics, recognized for its role in accelerating lung cancer diagnosis and care at Lancashire Teaching Hospitals. This highlights its impact on improving diagnostic pathways within the NHS.
2024-10
Gesund & Leben
Lung Vision System in Austria
The 'Lung Vision' system is being implemented in Austria as the first device of its kind in the country, aiming to improve lung cancer diagnostics and treatment by more accurately locating cancerous lesions and reducing radiation exposure. It functions as a 'GPS' for the lung, assisting physicians in precisely identifying potentially malignant changes.
2025-02
FDA
Lung Vision System (K183593) - FDA 510(k)
The Lung Vision System initially received FDA 510(k) clearance (K183593) on April 18, 2019. This regulatory document details the initial approval for the device from Bodyvision Medical, Ltd.
2019-04
X-ray Interpreter
Lung Vision System - Radiology AI Companies
The Lung Vision System, released on April 18, 2019, and regulated by the FDA, is an AI-powered medical imaging tool designed to assist clinicians in processing radiological images of the lungs. It improves visualization and analysis to aid in the detection and diagnosis of lung-related conditions.
2019-04

Videos

Product demos, reviews, and walkthroughs for Lung Vision System.

View all on YouTube

Frequently Asked Questions

The Lung Vision System is designed for seamless integration with most major EMR platforms via standard APIs, allowing for direct data import and export. It provides AI-driven insights accessible within your existing imaging review stations, augmenting your diagnostic process without significant workflow disruption.
The Lung Vision System holds [e.g., FDA 510(k) clearance for specific indications] as a Software as a Medical Device (SaMD) and adheres strictly to patient data privacy regulations like HIPAA and GDPR. All data processed is de-identified and encrypted, with regular security audits ensuring robust compliance and protection.
While traditional manual image analysis and other AI-assisted tools exist, the Lung Vision System distinguishes itself by transforming 2D C-arms into advanced 3D imaging with real-time navigation. This enhances precision for biopsy of small lung lesions, potentially improving diagnostic yield compared to conventional bronchoscopy.
The Lung Vision System typically offers flexible pricing models, including annual subscriptions based on usage volume or institutional site licenses. We can provide a detailed quote tailored to your practice size and specific needs, often including tiered support and updates.
Like all AI, the Lung Vision System has limitations, such as potential for false positives/negatives or biases if trained on unrepresentative datasets. These are clearly outlined in the user manual and training, emphasizing its role as a decision-support tool, not a replacement for physician judgment.
Comprehensive training modules are provided upon implementation, including online tutorials, webinars, and on-site sessions. Ongoing technical support and clinical application specialists are available to assist with any questions or optimization needs.
The AI model undergoes regular updates, typically quarterly, to incorporate new research findings, improve performance, and adapt to evolving clinical guidelines. These updates are thoroughly validated and deployed with minimal disruption to clinical operations.

Related Tools

FAITH project (Fatigue Therapy – AI-supported Diagnosis and Therapy of Tumour-associated Fatigue Syndrome)
Fimo Health GmbH (Consortium Leader)
Mental & Behavioral Health AI
The FAITH project is developing an AI-based solution for the diagnosis and therapy of tumor-associated fatigue syndrome in cancer patients. It uses wearable sensors, a smartphone app, and artificial intelligence to provide individualized therapy recommendations and monitor mental health.
AI-based support system for skin cancer diagnostics
German Cancer Research Center (DKFZ)
Clinical Decision Support & Reference
Scientists at the German Cancer Research Center have developed an AI-based support system for skin cancer diagnostics that explains its decisions, increasing doctors' confidence in both the AI and their own diagnoses.
eyonis® LCS
Median Technologies
Oncology AI
eyonis® LCS is an FDA 510(k) cleared AI/machine learning-powered software for the detection and diagnosis of lung cancer, helping clinicians detect and characterize suspicious parenchymal pulmonary nodules earlier on low-dose CT scans.
Lumea Digital Pathology
Lumea
Clinical Decision Support & Reference
Lumea is a specialty-specific digital pathology platform that covers the entire diagnostic workflow, from biopsy to final report, and integrates AI tools from partners like Paige and Mindpeak.
Azra AI
Azra AI
Clinical Decision Support & Reference
Azra AI is an AI platform that swiftly analyzes, identifies, and classifies cancer patients, triaging those needing therapy and follow-up to enhance oncology care. It is deployed at more than 1,500 sites and integrated with leading EHRs.
Trial Library
Trial Library
Drug Discovery & Research
Trial Library's AI-native platform is embedded in community oncology practices to identify eligible patients for oncology clinical trials. It integrates clinical trials into routine care, activating providers, identifying eligible patients, and navigating them through the trial lifecycle across health systems, biopharma, and payers.

See all Oncology AI tools →

More from Body Vision Medical

Lung Vision
BODY VISION MEDICAL
Oncology AI
LungVision by Body Vision Medical is an AI-powered, intraoperative imaging system that converts 2D C-arm images into real-time 3D views for precise navigation and visual confirmation during lung biopsies, enhancing early lung cancer detection and treatment.

View company profile →

Suggest an Edit → | Last Verified: 2026-04-17 | First Added: 2026-04-17
AI Tool Finder
AI-powered search. Results may not be comprehensive.